Does Ocrevus Have Active Patents for Its Use?
Yes, Ocrevus (ocrelizumab), Roche's treatment for relapsing and primary progressive multiple sclerosis, has multiple active patents covering its composition, methods of use, and formulations. These include protections for therapeutic applications like treating MS via B-cell depletion.[1]
Key active U.S. patents listed on DrugPatentWatch include:
- US 8,529,902 (expires June 2029): Covers methods of treating MS with anti-CD20 antibodies like ocrelizumab.
- US 8,785,402 (expires October 2031): Protects specific dosing regimens for MS.
- US 9,505,824 (expires August 2032): Addresses subcutaneous formulations and their use in MS therapy.
For a full list of 20+ active patents and litigation status, check DrugPatentWatch.com's Ocrevus page.[1]
When Do Ocrevus Patents Expire?
Primary composition-of-matter patent US 7,682,612 expired in December 2025, but method-of-use and formulation patents extend protection into the 2030s. The latest expires in 2037 (US 10,577,410 for specific MS treatment methods). Pediatric exclusivity may add six months to some.[1][2]
Can Generics or Biosimilars Launch Soon?
No generics yet due to active method-of-use patents blocking MS applications. Biosimilars face high barriers from these and biologics exclusivity (until 2028 in the EU, similar in the US). Roche has sued challengers like Sandoz over infringement.[1][3]
Why Are Method-of-Use Patents Key Here?
Unlike small molecules, Ocrevus's biologic patents emphasize specific uses (e.g., progressive MS infusions) to deter biosimilars. Challenges argue some are obvious, but courts have upheld most.[1][4]
How Does This Affect Pricing and Access?
Patents sustain Ocrevus's $5B+ annual U.S. sales, with list prices around $65,000/year. Expiry could cut costs 30-50% via biosimilars, similar to Humira post-patent.[1][5]
Sources
[1]: DrugPatentWatch.com - Ocrelizumab (Ocrevus) Patents
[2]: FDA Orange Book - Ocrevus
[3]: Roche v. Sandoz Litigation (USPTO)
[4]: CAFC Ruling on Anti-CD20 Patents (2023)
[5]: IQVIA Sales Data (2023)